Erratum: No influence of FAT polymorphisms in response to aripiprazole (Journal of Human Genetics (2010) 55 (32-36) DOI:10.1038/jhg.2009.117);No influence of FAT polymorphisms in response to aripiprazole

Journal of Human Genetics

Volumn 55, Issue 1, 2010, Pages 32-36

  Pae, Chi Un ^a,b   Chiesa, Alberto ^c   Mandelli, Laura ^c   De Ronchi, Diana ^c   Serretti, Alessandro ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aripiprazole; Cadherins; Pharmacogenetics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DYSBINDIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR 1 PRECURSOR GENE; TUMOR SUPPRESSOR GENE;

EID: 76149085183     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2009.128     Document Type: Erratum

References (26)

1. Goodwin, M. & Yap, A. S. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 35, 839-844 (2004).
2. Tepass, U., Truong, K., Godt, D., Ikura, M. & Peifer, M. Cadherins in embryonic and neural morphogenesis. Nat. Rev. Mol. Cell. Biol. 1, 91-100 (2000).
3. Yagi, T. & Takeichi, M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 14, 1169-1180 (2000). (Pubitemid 30327498)
4. Pedrosa, E., Stefanescu, R., Margolis, B., Petruolo, O., Lo, Y., Nolan, K. et al. Analysis of protocadherin alpha gene enhancer polymorphism in bipolar disorder and schizophrenia. Schizophr. Res. 102, 210-219 (2008).
5. Mahoney, P. A., Weber, U., Onofrechuk, P., Biessmann, H., Bryant, P. J. & Goodman, C. S. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 67, 853-868 (1991).
6. Jeanes, A., Gottardi, C. J. & Yap, A. S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920-6929 (2008).
7. Abou Jamra, R., Becker, T., Georgi, A., Feulner, T., Schumacher, J., Stromaier, J. et al. Genetic variation of the FAT gene at 4q35 is associated with bipolar affective disorder. Mol. Psychiatry 13, 277-284 (2008).
8. Blair, I. P., Chetcuti, A. F., Badenhop, R. F., Scimone, A., Moses, M. J., Adams, L. J. et al. Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Mol. Psychiatry 11, 372-383 (2006).
9. Friddle, C., Koskela, R., Ranade, K., Hebert, J., Cargill, M., Clark, C. D. et al. Fullgenome scan for linkage in 50 families segregating the bipolar affective disease phenotype. Am. J. Hum. Genet. 66, 205-215 (2000).
10. McInnis, M. G., Lan, T. H., Willour, V. L., McMahon, F. J., Simpson, S. G., Addington, A. M. et al. Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. Mol. Psychiatry 8, 288-298 (2003).
11. Willour, V. L., Zandi, P. P., Huo, Y., Diggs, T. L., Chellis, J. L., MacKinnon, D. F. et al. Genome scan of the fifty-six bipolar pedigrees from the NIMH genetics initiative replication sample: chromosomes 4, 7, 9, 18, 19, 20, and 21. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121, 21-27 (2003). (Pubitemid 37064025)
12. Porteous, D. Genetic causality in schizophrenia and bipolar disorder: out with the old and in with the new. Curr. Opin. Genet. Dev. 18, 229-234 (2008).
13. Ivleva, E., Thaker, G. & Tamminga, C. A. Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr. Bull. 34, 734-742 (2008).
14. Craddock, N., O'Donovan, M. C. & Owen, M. J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32, 9-16 (2006).
15. Pae, C. U., Serretti, A., Chiesa, A., Mandelli, L., Lee, C., Kim, J. et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur. Neuropsychopharmacol. 19, 562-570 (2009).
16. Guy, W. Clinical Global Impression. Assessment Manual for Psychopharmacology 217-222 (Department of Health Education and Welfare, Washington, DC, USA, 1976).
17. Flemenbaum, A. & Zimmermann, R. L. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol. Rep. 32, 783-792 (1973).
18. Andreasen, N. C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 7, 49-58 (1989).
19. Simpson, G. M. & Angus, J. W. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. Suppl. 212, 11-19 (1970).
20. Barnes, T. R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676 (1989).
21. Branch, P. R. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom. 4, 3-6 (1975).
22. StatSoft I: STATISTICA per Windows, StatSoft Italia srl, Vigonza (PD) (1995).
23. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
24. Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum, Hillsdale, New Jersey, 1988).
25. Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N. et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 13, 2699-2708 (2004).
26. Hwu, H. G., Lin, M. W., Lee, P. C., Lee, S. F., Ou-Yang, W. C. & Liu, C. M. Evaluation of linkage of markers on chromosome 6p with schizophrenia in Taiwanese families. Am. J. Med. Genet. 96, 74-78 (2000).